Malignant Pleural Mesothelioma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis

Malignant Pleural Mesothelioma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Malignant Pleural Mesothelioma pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Malignant Pleural Mesothelioma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.

 

Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years. 
  • Malignant Pleural Mesothelioma companies working in the treatment market are Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment 
  • Emerging Malignant Pleural Mesothelioma therapies in the different phases of clinical trials are- INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.   
  • In September 2022, The US FDA granted Pegargiminase Fast track status for mesothelioma treatment
  • In June 2022, In the United States (Intratumoural), Momotaro-Gene stated that enrollment in their phase II trial for mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or larger) had reached its completion
  • In March 2021, Merck & Co initiated a Pembrolizumab plus Lenvatinib in second line andthird line Malignant Pleural mesothelioma patients (PEMMELA). Currently the trial is active, not recruiting

 

 

Malignant Pleural Mesothelioma Overview

Patients with second- and third-line malignant pleural mesothelioma (PEMMELA) were given Pembrolizumab plus Lenvatinib. The trial is still ongoing and not recruiting participants.

 

Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight

 

Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:

  • INBRX-109: Inhibrx
  • NX-1607: Nurix Therapeutics
  • ATA2271: Atara Biotherapeutics
  • NGR-TNF: MolMed
  • Pembrolizumab : Merck & Co
  • Pegargiminase: Polaris Pharmaceuticals
  • Lurbinectedin: PharmaMar
  • YS110: Ys Therapeutics
  • TC-510: TCR2 Therapeutics
  • RSO-021: RS Oncology
  • SAR-444245: Sanofi
  • MTG201: MomotaroGene
  • Durvalumab: AstraZeneca
  • Pembrolizumab: Merck & Co

 

Route of Administration

Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment

  • Malignant Pleural Mesothelioma Assessment by Product Type
  • Malignant Pleural Mesothelioma By Stage and Product Type
  • Malignant Pleural Mesothelioma Assessment by Route of Administration
  • Malignant Pleural Mesothelioma By Stage and Route of Administration
  • Malignant Pleural Mesothelioma Assessment by Molecule Type
  • Malignant Pleural Mesothelioma by Stage and Molecule Type

 

DelveInsight’s Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies

 

Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:

Key companies developing therapies for Malignant Pleural Mesothelioma are – Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis,  MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.

 

Malignant Pleural Mesothelioma Pipeline Analysis:

The Malignant Pleural Mesothelioma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
  • Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies

 

Malignant Pleural Mesothelioma Pipeline Market Drivers

  • Increased adoption of combination therapies are some of the important factors that are fueling the Malignant Pleural Mesothelioma Market.

 

Malignant Pleural Mesothelioma Pipeline Market Barriers

  • However, treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, high Cost of Treatment and other factors are creating obstacles in the Malignant Pleural Mesothelioma Market growth.

 

Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight    

  • Coverage: Global
  • Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others
  • Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others
  • Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
  • Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers 

 

Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials

 

Table of Contents

1

Malignant Pleural Mesothelioma Report Introduction

2

Malignant Pleural Mesothelioma Executive Summary

3

Malignant Pleural Mesothelioma Overview

4

Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5

Malignant Pleural Mesothelioma Pipeline Therapeutics

6

Malignant Pleural Mesothelioma Late Stage Products (Phase II/III)

7

Malignant Pleural Mesothelioma Mid Stage Products (Phase II)

8

Malignant Pleural Mesothelioma Early Stage Products (Phase I)

9

Malignant Pleural Mesothelioma Preclinical Stage Products

10

Malignant Pleural Mesothelioma Therapeutics Assessment

11

Malignant Pleural Mesothelioma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Malignant Pleural Mesothelioma Key Companies

14

Malignant Pleural Mesothelioma Key Products

15

Malignant Pleural Mesothelioma Unmet Needs

16 

Malignant Pleural Mesothelioma Market Drivers and Barriers

17

Malignant Pleural Mesothelioma Future Perspectives and Conclusion

18

Malignant Pleural Mesothelioma Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services